Moleculin Biotech (NASDAQ:MBRX) Receives New Coverage from Analysts at StockNews.com

Research analysts at StockNews.com assumed coverage on shares of Moleculin Biotech (NASDAQ:MBRX) in a report released on Monday. The brokerage set a “sell” rating on the stock.

Moleculin Biotech Trading Up 0.4 %

NASDAQ:MBRX opened at $0.54 on Monday. The firm’s fifty day simple moving average is $0.47 and its 200 day simple moving average is $0.57. Moleculin Biotech has a twelve month low of $0.34 and a twelve month high of $1.65. The firm has a market capitalization of $16.10 million, a price-to-earnings ratio of -0.53 and a beta of 1.89.

Moleculin Biotech (NASDAQ:MBRX) last posted its earnings results on Friday, August 11th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.08. During the same period last year, the business posted ($0.24) earnings per share. On average, analysts predict that Moleculin Biotech will post -0.94 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Charles Schwab Investment Management Inc. bought a new position in Moleculin Biotech during the 4th quarter valued at $39,000. Renaissance Technologies LLC increased its stake in shares of Moleculin Biotech by 34.7% during the second quarter. Renaissance Technologies LLC now owns 127,400 shares of the company’s stock valued at $74,000 after acquiring an additional 32,795 shares during the period. Finally, State Street Corp lifted its position in shares of Moleculin Biotech by 19.2% during the 1st quarter. State Street Corp now owns 71,397 shares of the company’s stock valued at $127,000 after acquiring an additional 11,497 shares during the last quarter. 7.67% of the stock is currently owned by hedge funds and other institutional investors.

Moleculin Biotech Company Profile

Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs.